Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SLNO

Soleno Therapeutics Inc

Feb 10 • 04:00PM ET

40.50

-0.38 -0.93 %

Healthcare • Biotechnology • USA • NASD

Peers: VKTX RZLT MDGL LGND KURA ARDX ASRT ENTA PDSB BTAI

| Held by: VTI XBI IWM VXF IWO VTWO SCHA VHT ITOT LABU

Index	RUT	P/E	-	EPS (ttm)	-1.84	Insider Own	8.27%	Shs Outstand	53.70M	Perf Week	-7.91%
Market Cap	2.18B	Forward P/E	9.62	EPS next Y	4.21	Insider Trans	0.00%	Shs Float	49.27M	Perf Month	-5.81%
Enterprise Value	1.73B	PEG	-	EPS next Q	0.71	Inst Own	117.47%	Short Float	21.18%	Perf Quarter	-15.09%
Income	-78.45M	P/S	22.05	EPS this Y	106.69%	Inst Trans	18.96%	Short Ratio	6.60	Perf Half Y	-52.78%
Sales	98.67M	P/B	4.40	EPS next Y	1336.48%	ROA	-17.50%	Short Interest	10.44M	Perf YTD	-12.53%
Book/sh	9.21	P/C	4.36	EPS next 5Y	-	ROE	-20.66%	52W High	90.32 -55.16%	Perf Year	-19.34%
Cash/sh	9.29	P/FCF	-	EPS past 3/5Y	9.02% 20.19%	ROIC	-14.35%	52W Low	37.95 6.72%	Perf 3Y	1792.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.12%	Volatility	5.39% 5.38%	Perf 5Y	-11.48%
Dividend TTM	-	EV/Sales	17.52	EPS Y/Y TTM	44.84%	Oper. Margin	-85.40%	ATR (14)	2.32	Perf 10Y	-55.38%
Dividend Ex-Date	-	Quick Ratio	15.88	Sales Y/Y TTM	-	Profit Margin	-79.50%	RSI (14)	42.61	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	16.08	EPS Q/Q	125.89%	SMA20	-3.50%	Beta	-3.18	Target Price	111.92
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	-11.47%	Rel Volume	0.49	Prev Close	40.88
Employees	92	LT Debt/Eq	0.11	Earnings	Nov 04 AMC	SMA200	-37.09%	Avg Volume	1.58M	Price	40.50
IPO	Nov 13, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	717.39% 37.27%	Trades		Volume	780,016	Change	-0.93%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wolfe Research	Outperform	$75
Oct-07-25	Initiated	Goldman	Buy	$125
Aug-20-25	Initiated	Wells Fargo	Overweight	$123
Jun-23-25	Initiated	TD Cowen	Buy	$110
Mar-05-25	Resumed	Stifel	Buy	$74
Dec-02-24	Reiterated	Stifel	Buy	$74
Dec-02-24	Reiterated	Robert W. Baird	Outperform	$72
Sep-03-24	Initiated	H.C. Wainwright	Buy	$70
May-10-24	Initiated	Robert W. Baird	Outperform	$72
Feb-05-24	Initiated	Piper Sandler	Overweight	$93
Jan-23-24	Initiated	Stifel	Buy	$63
Nov-21-23	Resumed	Guggenheim	Buy	$40
Sep-29-20	Initiated	Guggenheim	Buy	$8
Jan-10-20	Initiated	Craig Hallum	Buy	$8
Dec-23-19	Initiated	Oppenheimer	Outperform	$10
Feb-13-18	Reiterated	Maxim Group	Buy	$8 → $4

Show Previous Ratings

Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks) +9.75%
09:35AM	Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
Jan-29-26 08:00AM	Soleno Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Jan-27-26 12:59PM	HCA Healthcare Q4 Earnings Beat Estimates on Strong Patient Volumes (Zacks)
07:22AM	Loading…
07:22AM	Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge (Insider Monkey)
Jan-23-26 04:56AM	Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now? (Insider Monkey)
Jan-22-26 10:21PM	Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside (Insider Monkey)
Jan-14-26 09:55AM	Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Jan-13-26 04:28AM	New Strong Buy Stocks for January 13th (Zacks)
Jan-12-26 07:00AM	Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Jan-09-26 03:16AM	Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts (Insider Monkey) -5.49%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-06-26 08:00AM	Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)? (Insider Monkey)
08:00AM	Loading…
Jan-05-26 08:00AM	Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT XR in the Journal of Clinical Endocrinology and Metabolism (GlobeNewswire)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +5.07%
Dec-10-25 10:32AM	Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026? (Insider Monkey)
Dec-03-25 04:05PM	Soleno Therapeutics Announces the Passing of Board Member William G. Harris (GlobeNewswire) +5.41%
Nov-30-25 12:26AM	Analyst Dismisses ViCAT XR Safety Fears, Expects Strong Growth Despite Recent Stock Weakness (Insider Monkey)
Nov-25-25 08:39AM	Soleno Therapeutics (SLNO) Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns (Insider Monkey) +8.41%
Nov-24-25 08:00AM	Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-21-25 05:22AM	Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns (Insider Monkey)
Nov-11-25 07:00AM	Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement (GlobeNewswire) +5.16%
Nov-07-25 10:04AM	Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman (PR Newswire) +9.55%
Nov-06-25 12:07PM	Soleno Therapeutics (SLNO) Ends 26% Lower After Q3 Earnings (Insider Monkey) -7.10%
Nov-05-25 06:26AM	Soleno slumps despite sales uptick; Madrigals MASH drug continues ascent (BioPharma Dive) -26.59%
12:03AM	Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Call Highlights: Profitability Achieved Amidst ... (GuruFocus.com)
Nov-04-25 04:01PM	Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR (GlobeNewswire)
Nov-03-25 07:28AM	Soleno Therapeutics Inc (SLNO) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
08:00AM	Loading…
Oct-28-25 08:00AM	Soleno Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire)
Oct-22-25 05:01PM	Soleno Therapeutics, Inc. (SLNO): A Bull Case Theory (Insider Monkey)
Oct-21-25 08:00AM	Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET (GlobeNewswire)
Oct-17-25 09:54PM	Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating (Insider Monkey)
Oct-13-25 08:00AM	Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors (GlobeNewswire)
Oct-07-25 01:05PM	Piper Sandler Maintains a Buy Rating on Soleno Therapeutics (SLNO), Sets a $145 PT (Insider Monkey) +6.26%
Sep-30-25 04:01AM	Wells Fargo Reiterates a Buy Rating on Soleno Therapeutics (SLNO), Sets a PT of $123 (Insider Monkey)
Sep-25-25 10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
10:23AM	Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial (Insider Monkey)
Sep-24-25 04:20PM	Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges (Investor's Business Daily) +13.46%
07:28AM	Acadia to scrap Prader-Willi drug after study setback (BioPharma Dive)
Sep-18-25 10:38AM	Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands (Insider Monkey) +10.98%
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive) -5.47%
Sep-11-25 09:35AM	Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.49%
02:18AM	Soleno Therapeutics (SLNO) Falls Hard on Patient Death (Insider Monkey)
Sep-10-25 12:59AM	Here's Why Analysts are Bullish on Soleno Therapeutics (SLNO) (Insider Monkey) -14.52%
Aug-27-25 08:00AM	Soleno Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-20-25 04:02PM	Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman (PR Newswire)
09:34AM	Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls (The Fly)
Aug-19-25 09:35AM	Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround (Zacks)
Aug-15-25 09:57AM	Soleno Therapeutics stock falls after Scorpion Capital short report (Investing.com) -7.41%
Aug-11-25 09:55AM	How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% (Zacks)
08:50AM	Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going (Zacks)
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 08:00AM	Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET (GlobeNewswire)
Jul-25-25 12:00PM	Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy? (Zacks)
Jul-23-25 09:55AM	Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength (Zacks)
Jul-21-25 12:15AM	Soleno Therapeutics' Vykat XR Exceeds Sales Expectations (Insider Monkey)
Jul-10-25 09:59AM	Soleno sales of new Prader-Willi drug rise faster than expected (BioPharma Dive) -9.23%
09:07AM	Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (GlobeNewswire)
06:01AM	Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock (GlobeNewswire)
06:00AM	Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 (GlobeNewswire)
Jul-01-25 08:00AM	Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 (GlobeNewswire)
Jun-26-25 03:24PM	TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy (Insider Monkey)
Jun-25-25 08:00AM	Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
Jun-23-25 09:38AM	DoorDash, AMD upgraded: Wall Street's top analyst calls (The Fly)
Jun-20-25 08:00AM	Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
May-26-25 09:16AM	EMA validates Solenos application for Prader-Willi syndrome treatment (Pharmaceutical Technology)
May-23-25 05:40PM	Soleno Therapeutics seeking regulatory approval in treatment of PWS (TipRanks)
01:55AM	Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR (Insider Monkey)
May-22-25 05:32PM	Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome (GlobeNewswire)
May-21-25 08:00AM	Soleno Therapeutics to Participate in Upcoming June Conferences (GlobeNewswire)
May-20-25 04:05PM	Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome (GlobeNewswire)
May-15-25 08:00AM	Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 (GlobeNewswire)
May-13-25 07:00AM	Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 (GlobeNewswire)
May-11-25 05:26PM	Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
May-08-25 04:05PM	Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025 (GlobeNewswire)
03:30AM	Soleno Therapeutics Inc (SLNO) Q1 2025 Earnings Call Highlights: Navigating Early Success and ... (GuruFocus.com)
May-07-25 10:30PM	Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:01PM	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-06-25 08:50AM	Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-23-25 02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
07:00AM	Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET (GlobeNewswire)
Apr-14-25 07:00AM	Soleno Therapeutics Announces VYKAT(TM) XR Launch (GlobeNewswire)
Mar-29-25 10:39PM	Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? (Insider Monkey)
Mar-28-25 10:30PM	Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? (Insider Monkey) +6.83%
04:25AM	Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? (Insider Monkey)
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) +37.61%
04:11PM	Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger (Bloomberg)
03:40PM	Soleno wins FDA approval for Prader-Willi hyperphagia treatment (Pharmaceutical Technology)
02:50PM	Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SeekingAlpha)
12:11PM	Soleno stock skyrockets on FDA drug approval (Yahoo Finance Video)
08:46AM	SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-26-25 05:15PM	Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome (GlobeNewswire)
01:15PM	First Prader-Willi drug to reduce hunger approved by FDA (BioPharma Dive)
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha)
Feb-27-25 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire) +8.51%
Jan-29-25 04:05PM	Soleno Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Abingworth Bioventures VII LP	Shareholder	Aug 11 '25	Proposed Sale	82.15	1,347,522	110,696,581		Aug 15 09:00 PM
Hirano Patricia C	SEE REMARKS	Jul 01 '25	Sale	82.76	3,830	316,971	13,206	Jul 03 04:41 PM
PATRICIA HIRANO	Officer	Jul 01 '25	Proposed Sale	82.76	3,830	316,971		Jul 01 04:03 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Option Exercise	44.25	266	11,770	17,302	Jun 26 06:04 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Sale	84.25	266	22,410	17,036	Jun 26 06:04 PM
PATRICIA HIRANO	Officer	Jun 24 '25	Proposed Sale	84.25	266	22,410		Jun 24 04:07 PM
Hirano Patricia C	SEE REMARKS	Apr 01 '25	Sale	70.11	3,782	265,156	27,036	Apr 02 05:38 PM
PATRICIA HIRANO	Officer	Apr 01 '25	Proposed Sale	70.11	3,782	265,156		Apr 01 04:16 PM
Pauls Matthew	Director	Mar 28 '25	Option Exercise	4.60	5,937	27,310	12,437	Mar 31 07:24 PM
Pauls Matthew	Director	Mar 28 '25	Sale	71.55	5,937	424,797	6,500	Mar 31 07:24 PM
Yen Kristen	SEE REMARKS	Mar 27 '25	Option Exercise	4.97	40,638	201,966	101,774	Mar 31 07:23 PM
Yen Kristen	SEE REMARKS	Mar 27 '25	Sale	66.77	95,500	6,376,789	28,143	Mar 31 07:23 PM
Manning Meredith	Chief Commercial Officer	Mar 27 '25	Option Exercise	46.31	37,000	1,713,470	82,351	Mar 31 07:21 PM
Manning Meredith	Chief Commercial Officer	Mar 27 '25	Sale	67.28	45,249	3,044,343	45,351	Mar 31 07:21 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Mar 27 '25	Option Exercise	11.72	70,000	820,125	175,176	Mar 31 07:20 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Mar 27 '25	Sale	69.44	90,622	6,293,177	105,176	Mar 31 07:20 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '25	Option Exercise	21.93	10,000	219,300	46,817	Mar 31 07:18 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '25	Sale	69.51	14,583	1,013,627	36,817	Mar 31 07:18 PM
Hirano Patricia C	SEE REMARKS	Mar 27 '25	Option Exercise	7.19	72,140	518,557	166,913	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 28 '25	Option Exercise	33.60	2,691	90,418	58,480	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 27 '25	Sale	68.32	128,653	8,789,717	55,789	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 28 '25	Sale	69.40	27,662	1,919,636	30,818	Mar 31 07:01 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Mar 27 '25	Option Exercise	12.17	523,809	6,373,861	1,100,885	Mar 31 07:00 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Mar 27 '25	Sale	67.62	699,095	47,271,960	577,076	Mar 31 07:00 PM
Vivo Opportunity, LLC	10% Owner	Mar 27 '25	Sale	67.80	1,100,000	74,580,000	4,791,851	Mar 28 07:03 PM
Vivo Opportunity, LLC	10% Owner	Mar 26 '25	Sale	65.80	400,000	26,320,000	5,891,851	Mar 28 07:03 PM
Vivo Opportunity, LLC	10% Owner	Mar 28 '25	Sale	70.60	333,557	23,549,124	4,458,294	Mar 28 07:03 PM
PATRICIA HIRANO	Officer	Mar 28 '25	Proposed Sale	69.40	27,662	1,919,636		Mar 28 04:09 PM
Matthew Pauls	Officer	Mar 28 '25	Proposed Sale	67.39	5,937	400,094		Mar 28 12:45 PM
PATRICIA HIRANO	Officer	Mar 27 '25	Proposed Sale	68.31	111,124	7,591,418		Mar 27 04:15 PM
Kristen Yen	Officer	Mar 27 '25	Proposed Sale	50.05	97,006	4,855,150		Mar 27 08:57 AM
Meredith Manning	Officer	Mar 27 '25	Proposed Sale	50.05	48,000	2,402,400		Mar 27 08:56 AM
James H Mackaness	Officer	Mar 27 '25	Proposed Sale	50.05	92,500	4,629,625		Mar 27 08:55 AM
Michael F. Huang	Officer	Mar 27 '25	Proposed Sale	50.05	29,625	1,482,731		Mar 27 08:55 AM
Patricia C Hirano	Officer	Mar 27 '25	Proposed Sale	50.05	23,375	1,169,919		Mar 27 08:54 AM
Bhatnagar Anish	Officer	Mar 27 '25	Proposed Sale	50.05	746,041	37,339,352		Mar 27 08:53 AM

Open in Screener

SVRA

Savara Inc

Feb 10 • 04:00PM ET

5.27

+0.04 0.76 %

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM VXF XBI IWO VTWO IBB SCHA LFSC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	49.66%	Shs Outstand	172.85M	Perf Week	-6.89%
Market Cap	1.07B	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.02%	Shs Float	102.42M	Perf Month	-9.29%
Enterprise Value	977.72M	PEG	-	EPS next Q	-0.12	Inst Own	39.04%	Short Float	20.47%	Perf Quarter	33.42%
Income	-115.64M	P/S	-	EPS this Y	-7.26%	Inst Trans	-0.98%	Short Ratio	8.31	Perf Half Y	95.19%
Sales	0.00M	P/B	9.65	EPS next Y	14.54%	ROA	-60.91%	Short Interest	20.96M	Perf YTD	-12.60%
Book/sh	0.55	P/C	8.62	EPS next 5Y	38.07%	ROE	-78.74%	52W High	7.01 -24.77%	Perf Year	88.89%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	-14.63% 24.35%	ROIC	-93.14%	52W Low	1.89 178.84%	Perf 3Y	115.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.75% 5.58%	Perf 5Y	184.86%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.39%	Oper. Margin	-	ATR (14)	0.33	Perf 10Y	-67.27%
Dividend Ex-Date	-	Quick Ratio	7.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.65	EPS Q/Q	-19.30%	SMA20	-7.53%	Beta	0.33	Target Price	10.81
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	-12.21%	Rel Volume	0.80	Prev Close	5.23
Employees	59	LT Debt/Eq	0.32	Earnings	Nov 12 AMC	SMA200	35.89%	Avg Volume	2.52M	Price	5.27
IPO	Oct 16, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.66% -	Trades		Volume	2,002,912	Change	0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$7
Aug-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
08:05AM	Loading…
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
09:43PM	Loading…
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
09:00AM	Loading…
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17 04:38 PM
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23 02:39 PM
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02 07:59 AM
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01 07:00 AM

SLNO

Soleno Therapeutics Inc

SVRA

Savara Inc

Upgrade your FINVIZ experience